WHO Essential List Status Has Not Fixed GLP-1 Access

The addition of GLP-1 receptor agonists to the World Health Organization’s Model List of Essential Medicines should have marked a turning point for global diabetes care. Instead, access remains uneven, expensive, and tightly constrained in the places where the burden of chronic metabolic disease is rising fastest. This JAMA Perspective focuses on the gap between formal recognition of clinical value and the practical reality of obtaining these drugs in routine care, especially in low- and middle-income countries.

The policy signal is powerful. Essential medicine designation means a therapy has been judged important enough for broad public health use, not just for specialty clinics or wealthy health systems. Yet that designation does not manufacture vials, lower list prices, expand cold-chain distribution, or persuade payers to cover treatment. In many settings, patients who could benefit from GLP-1 receptor agonists are still separated from them by cost, procurement delays, supply limits, and fragile reimbursement systems.

The problem is structural, not pharmacologic.

Clinical Demand Is Outpacing Affordability

GLP-1 receptor agonists have become central to the management of type 2 diabetes and, in some settings, obesity-related cardiometabolic risk. Their appeal rests on mechanisms that matter at the bedside: glucose-dependent insulin secretion, suppression of glucagon, delayed gastric emptying, and effects on appetite and body weight. Those biologic effects translate into a class that can do more than lower blood sugar alone. In real-world practice, that broader profile has made these agents highly desirable, which only deepens the access problem when the market cannot meet demand equitably.

For health systems with constrained budgets, every new high-value therapy creates a difficult allocation decision. A medicine can be clinically valuable and still remain out of reach if procurement programs cannot absorb its cost. In lower-resource settings, the consequence is not abstract. A drug that could help control hyperglycemia, reduce treatment inertia, and support weight management may never reach the patient who needs it most.

This tension sits at the center of the Perspective. Essential medicines are supposed to function as a floor for access, not a ceiling for aspiration. When a class with strong cardiometabolic utility remains inaccessible, the label loses much of its public health force.

Price, Patents, and Supply Barriers Dominate the Access Gap

High prices are the most immediate obstacle, but they are not the only one. Patent protection, market concentration, limited manufacturing capacity, and unequal purchasing power all reinforce scarcity. Even when a health ministry wants to include a therapy in national formularies, the downstream system must still procure it reliably and at a sustainable price. Without that infrastructure, inclusion on a list can become symbolic rather than actionable.

Distribution also matters. Medicines that require steady cold storage or careful supply coordination expose weaknesses in pharmacy networks that are already stretched by insulin, antihypertensives, and other chronic therapies. In some countries, even basic continuity of supply is difficult to guarantee. A premium biologic or peptide-based therapy then becomes a luxury product by default, regardless of its clinical merit.

The access problem is especially sharp for chronic diseases, where interruption of therapy can erase the benefits of initial prescribing. Patients who start and then lose access face a cycle of treatment instability that health systems know too well. For a class designed for long-term metabolic control, intermittent availability is a particularly poor fit.

Essential Medicine Status Demands Policy, Not Symbolism

WHO inclusion should trigger concrete action. National formularies, pooled procurement strategies, generic competition where feasible, and pricing negotiations all become more urgent once a therapy is recognized as essential. Governments and global health agencies can use that status to justify broader coverage, negotiate lower prices, and prioritize distribution pathways that reach primary care rather than only tertiary centers.

The Perspective also points toward a deeper ethical issue. If a drug class is judged essential for one part of the world, access should not depend on geography alone. Patients in low- and middle-income countries carry a rising burden of diabetes and obesity-related illness, yet they are often the last to benefit from innovations that were developed in much wealthier markets. That mismatch is not just unfair; it weakens the public health value of the medicine itself.

A sustainable response would likely require more than one tactic. Differential pricing may help. So may local manufacturing partnerships, stronger generic pathways when patents expire, and procurement models that reduce the fragmentation of national buying power. Health systems also need prescribing frameworks that target the patients most likely to benefit, so limited supply is not wasted on inconsistent or inappropriate use.

The Bedside Consequence Is Simple

Patients cannot benefit from a medicine they cannot obtain.

That sentence captures the clinical meaning of the access debate. A therapy with established biologic plausibility and expanding utility remains only partially useful if it is unavailable in the places where it is needed most. The move onto the WHO Essential Medicines List may strengthen the argument for wider adoption, but it does not solve the practical barriers that keep treatment out of reach.

The Perspective leaves the field with a concrete challenge: turn essential status into reliable access. Until pricing, procurement, and supply systems are aligned with clinical need, GLP-1 receptor agonists will remain essential on paper and inaccessible in practice.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by JAMA (Journal of the American Medical Association).